OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • The OncLive Insider app is live!
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Treatment Approaches in Advanced Urothelial Cancer

home / insights / treatment-approaches-in-advanced-urothelial-cancer

Insight regarding the utilization of antibody-drug conjugate therapy to treat relapsed/refractory advanced bladder cancer.

GU oncologist

EP. 1: Advanced Bladder Cancer: Adopting Newer Therapies into Clinical Practice

Bradley McGregor, MD
February 3rd 2022

Bradley McGregor, MD, reacts to treatment advances for advanced bladder cancer and shares perspective on utilizing newer, novel therapies as the field continues to evolve

Benjamin Miron, MD

EP. 2: Encouraging Developments in Therapies for Relapsed/Refractory Advanced Bladder Cancer

Benjamin Miron, MD
February 7th 2022

Dr Benjamin Miron highlights data specific to treating patients with relapsed metastatic disease.

Vadim Koshkin, MD

EP. 3: Treating R/R Advanced Bladder Cancer With Novel Sequencing Strategies

Vadim S. Koshkin, MD
February 7th 2022

UCSF Health’s Vadim S. Koshkin, MD, highlights approaches for sequencing novel therapies into treatment algorithms for patients with relapsed/refractory advanced bladder cancer.

Ali R. Khaki, MD

EP. 4: Study EV-103 in Advanced Bladder Cancer

Ali R. Khaki, MD
February 7th 2022

Ali R. Khaki, MD, describes the impact of the EV-103 study of enfortumab vedotin in advanced bladder cancer.

Ali Khaki, MD

EP. 5: Optimizing Therapy for Patients with Advanced Bladder Cancer

Ali R. Khaki, MD
February 7th 2022

Ali R. Khaki, MD, comments on how to treat patients with advanced bladder cancer based on data demonstrated by the EV-103 study of enfortumab vedotin.

Latest Conference Coverage

Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL

MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL

Isa-KRd Yields Prolonged MRD Negativity vs KRd in Newly Diagnosed Myeloma

Elranatamab Triplet Yields Nearly 100% ORR in Newly Diagnosed Multiple Myeloma

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Download on Apple
© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact